Skip to main content
. 2018 May 3;3(9):e99672. doi: 10.1172/jci.insight.99672

Figure 3. The t test and ROC curve analysis results from the 0–I and II–IV aGVHD groups of patients.

Figure 3

The t test and ROC curve analyses showed differences in PA, SA, and the SA/PA ratio between the two groups of patients in the discovery set (A, B, and C; n = 28; P < 0.05, AUC > 0.7). The SA/PA ratio was more effective in the diagnosis of II–IV aGVHD compared with each of the two metabolite biomarkers alone. These data are confirmed by the results from the validation data set (D; n = 86; P < 0.01, AUC = 0.719).